학술논문
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.
Document Type
journal article
Author
Reungwetwattana T; Molina JR; Mandrekar SJ; Allen-Ziegler K; Rowland KM; Reuter NF; Luyun RF; Dy GK; Marks RS; Schild SE; Jett JR; Adjei AA; Reungwetwattana, Thanyanan; Molina, Julian R; Mandrekar, Sumithra J; Allen-Ziegler, Katie; Rowland, Kendrith M; Reuter, Nicholas F; Luyun, Ronnie F; Dy, Grace K
Source
Journal of Thoracic Oncology; 2012 May, Vol. 7 Issue 5, p919-922, 4p
Subject
Language
ISSN
15560864